January 30, 2015 2:30 PM ET

Biotechnology

Company Overview of Organovo Holdings, Inc.

Company Overview

Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-...

6275 Nancy Ridge Drive

Suite 110

San Diego, CA 92121

United States

Founded in 2007

60 Employees

Phone:

858-550-9994

Key Executives for Organovo Holdings, Inc.

Chairman
Age: 42
Total Annual Compensation: $362.9K
Chief Financial Officer
Age: 64
Total Annual Compensation: $289.1K
Chief Strategy Officer
Age: 42
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice President of Research & Development
Age: 45
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operations
Age: 55
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.

Organovo Holdings, Inc. Key Developments

ONVO Mulls Acquisitions

Organovo Holdings, Inc. (AMEX:ONVO) is seeking acquisitions. ONVO may offer and sell shares of ONVO's common stock, par value $0.001 per share, having an aggregate offering price of up to $33 million. ONVO intends to use the net proceeds for general corporate purposes, including research and development, the development and commercialization of ONVO’s products, general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

Organovo Holdings, Inc. Appoints Kirk D. Malloy to Board of Directors

Organovo Holdings, Inc. announced Kirk D. Malloy, Ph.D. has been appointed to the Company's Board of Directors. He is currently Senior Vice President and General Manager of Life Sciences at Illumina.

Organovo Holdings, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:55 AM

Organovo Holdings, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:55 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Keith Murphy, Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee.

Similar Private Companies By Industry

Company Name Region
3-V Biosciences, Inc. United States
Periphagen Holdings, Inc. United States
VICAM LP United States
APSE, LLC United States
Ablitech, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Organovo Holdings, Inc., please visit www.organovo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.